Johnson & Johnson (BUE:JNJ) Net Interest Margin (Bank Only) %


BUE:JNJ Johnson & Johnson BUE:JNJ
73 GF Score
Price ARS28,160.00
GF Value ARS20,124.22
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

BUE:JNJ
73GF Score
Johnson & Johnson BUE:JNJ
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Johnson & Johnson (BUE:JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of ARS28,160.00 is trading 39.9% above its estimated GF Value™ of ARS20,124.22. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for BUE:JNJ:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: ARS20,124.22 vs. price of ARS28,160.00 (39.9% above fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the BUE:JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
73GF Score

Get the complete analysis for BUE:JNJ

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS28,160.00
Price
ARS20,124.22
GF Value